NCT03121300

Brief Summary

Little is known about the safety of body radiation therapy (SBRT), especially the impact on pulmonary function, quality of life, and on functional changes within the lung itself. Radiation dose constraints and capturing functional changes on imaging are not well studied in this setting. The current study aims to evaluate the utility of advanced imaging to measure lung function prior to and after treatment and to assess the feasibility of using this data to adapt SBRT planning.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 6, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 14, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 20, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2019

Completed
Last Updated

October 17, 2019

Status Verified

October 1, 2019

Enrollment Period

2.6 years

First QC Date

April 14, 2017

Last Update Submit

October 16, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Longitudinal Changes in Lung Function

    To characterize longitudinal changes in lung function using SPECT/CT and CT ventilation scans in "high risk" patients undergoing standard SBRT treatments.

    From baseline to 6 months post Radiation Treatment

Secondary Outcomes (3)

  • Dosimetric Predictors to Assess Changes in Toxicity

    From baseline to 6 months post Radiation Treatment

  • Changes in SPECT-CT Correlate with Changes in CT Ventilation

    From baseline to 6 months post Radiation Treatment

  • To Assess Early Vascular Changes Using DCE-MRI

    From baseline to 6 months post Radiation Treatment

Other Outcomes (1)

  • Changes in Cardiac Function

    From baseline to 6 months post Radiation Treatment

Study Arms (1)

High Risk Lung Cancer Patients

Other: CT ScanOther: Lung CTOther: MRIOther: Walk TestOther: SGRQOther: Biological Sample CollectionOther: ToxicityOther: Cardiac Assessment

Interventions

CT ScanOTHER

Quantitative lung SPECT-CT

High Risk Lung Cancer Patients
Lung CTOTHER

CT lung ventilation

High Risk Lung Cancer Patients
MRIOTHER

DCE MRI

High Risk Lung Cancer Patients

6 minute hall walk test

High Risk Lung Cancer Patients
SGRQOTHER

St. George Respiratory Questionnaire

High Risk Lung Cancer Patients

Blood Draw

High Risk Lung Cancer Patients

Toxicity Evaluation

High Risk Lung Cancer Patients

Cardiac MRI Scan

High Risk Lung Cancer Patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

High Risk Lung Cancer Patients

You may qualify if:

  • Patients receiving SBRT lung treatment and who have any one of the following high risk features:
  • Lung lesion \> 5 cm
  • DLCO \< 35%
  • FEV1 \< 0.5 L
  • Central lung tumors (defined as within 2 cm from the proximal bronchial tree)
  • Tumors that abut the great vessels, trachea, spinal cord, or esophagus
  • Prior lobectomy or pneumonectomy
  • Prior lung radiation (SBRT or conventional definitive lung radiation)
  • Patients must be 18 years of age or older

You may not qualify if:

  • Patients who have received targeted agents or systemic potentially radiosensitizing chemotherapy within 2 weeks of lung SBRT start
  • Pregnancy or lactation
  • Unable to tolerate MRI without anesthesia
  • Inability cooperate with the scans

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Patients will have 20 mL of blood collected by venipuncture at the specified time points.

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Shruti Jolly, M.D.

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2017

First Posted

April 20, 2017

Study Start

February 6, 2017

Primary Completion

August 30, 2019

Study Completion

August 30, 2019

Last Updated

October 17, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations